A case study titled “Probiotics for Chronic Kidney Disease: The “Renadyl” Story” was presented by Kibow at Microbiome/Microbiota R&D and Business Collaboration Forum at San Diego, California in the year 2015. The case study highlights the bad effects of Chronic Kidney Disease on various parts of the human body and reflected on several challenges a patient has to undergo to get through with this painful disease. The case study also highlights how this disease weakens the good bacteria and severely stunts your health. The main objectives of the case study are to highlight how Kibow’s “Renadyl” product effectively counteracts this disease by providing the gut flora with essential good bacteria to fight with the disease. “Renadyl” products make sure that the deficiency of good bacteria is eliminated and thus leaves no room for the growth of Chronic Kidney DIsease. There were three clinical trial results and corresponding results were received from them.
A case study titled “Probiotics for Chronic Kidney Disease: The “Renadyl” Story” was presented by Kibow at Microbiome/Microbiota R&D and Business Collaboration Forum at San Diego, California in the year 2015. The case study highlights the bad effects of Chronic Kidney Disease on various parts of the human body and reflected on several challenges a patient has to undergo to get through with this painful disease. The case study also highlights how this disease weakens the good bacteria and severely stunts your health. The main objectives of the case study are to highlight how Kibow’s “Renadyl” product effectively counteracts this disease by providing the gut flora with essential good bacteria to fight with the disease. “Renadyl” products make sure that the deficiency of good bacteria is eliminated and thus leaves no room for the growth of Chronic Kidney DIsease. There were three clinical trial results and corresponding results were received from them.
A case study titled “Probiotics for Chronic Kidney Disease: The “Renadyl” Story” was presented by Kibow at Microbiome/Microbiota R&D and Business Collaboration Forum at San Diego, California in the year 2015. The case study highlights the bad effects of Chronic Kidney Disease on various parts of the human body and reflected on several challenges a patient has to undergo to get through with this painful disease. The case study also highlights how this disease weakens the good bacteria and severely stunts your health. The main objectives of the case study are to highlight how Kibow’s “Renadyl” product effectively counteracts this disease by providing the gut flora with essential good bacteria to fight with the disease. “Renadyl” products make sure that the deficiency of good bacteria is eliminated and thus leaves no room for the growth of Chronic Kidney DIsease. There were three clinical trial results and corresponding results were received from them.
A case study titled “Probiotics for Chronic Kidney Disease: The “Renadyl” Story” was presented by Kibow at Microbiome/Microbiota R&D and Business Collaboration Forum at San Diego, California in the year 2015. The case study highlights the bad effects of Chronic Kidney Disease on various parts of the human body and reflected on several challenges a patient has to undergo to get through with this painful disease. The case study also highlights how this disease weakens the good bacteria and severely stunts your health. The main objectives of the case study are to highlight how Kibow’s “Renadyl” product effectively counteracts this disease by providing the gut flora with essential good bacteria to fight with the disease. “Renadyl” products make sure that the deficiency of good bacteria is eliminated and thus leaves no room for the growth of Chronic Kidney DIsease. There were three clinical trial results and corresponding results were received from them.
Chronic Kidney Disease (CKD) is a growing Levels of urea, uric acid, creatinine, CRP, and health problem worldwide. CKD patients have the lesser known toxic metabolite (IG) arising high levels of inflammation, and their blood from protein putrefaction due to gut dysbiosis in uremic toxins passively diffuse into the bowel. CKD, can be reduced using some specific A novel probiotic supplement formulation was probiotic strains with improved QOL. Use of developed, after a decade of R&D, for the genetically engineered probiotics will be removal of several uremic toxins diffused and daunting in terms of development costs and US also generated by the gut microbiome. Thus FDA governmental regulations. our product ‘RENADYL™’ is targeted to help and restore/maintain kidney function in CKD References patients. 1. CKD impairs barrier function and alters microbial flora Objectives of the intestine: a major link to inflammation and uremic toxicity. Nosratola D Vaziri. 1. Gut dysbiosis and inflammation are related Curr Opin Nephrol Hypertens, 2012, 21(6): 587–592. to various diseases including Chronic Kidney 2. Chronic kidney disease alters intestinal microbial flora. Nosratola D. Vaziri, Jakk Wong, Madeleine Pahl et al. Disease1. Kidney International,2013, 83: 308–315 2. Chronic Kidney Disease is accompanied by 3. Alterations of intestinal barrier and microbiota in altered gut microbiome2,3. chronic kidney disease. Alice Sabatino, Giuseppe 3. Some specific probiotic strains can remove Regolisti, Irene Brusasco et al. uremic toxins, reduce inflammation and restore Nephrol Dial Transplant ,2014, 0: 1–10 the gut microflora balance4,5. 4. Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update. Alessandro Di Cerbo, Federica Pezzuto, Lucia Palmieri. Methods Int Urol Nephrol,2013,45:1569–1576 5. Pre-, Pro-, and Synbiotics: Do They Have a Role in Reducing Uremic Toxins? A Systematic Review and Earlier attempts to genetically engineer a Meta-Analysis.Megan Rossi, David W Johnson et al. microbe with various genes – urease, International Journal of Nephrology, creatininase and uricase were technically difficult Volume 2012 (2012), Article ID 673631, 20 pages and unsuccessful. Secondly, the possible Open label dose escalation study in 28 patients 6. Probiotic Amelioration of Azotemia in 5/6th challenges from USFDA for use in highly nephrectomized Sprague-Dawley rats, Ranganathan, for a period of 6 months at Thomas Jefferson immunocompromised CKD patients led us to Natarajan ; Patel, Beena ; Ranganathan, Pari ;Marczely, University showed no adverse effects with Joseph ; Dheer, Rahul ; Chordia, Tushar ; Dunn, drop this route, and opt for naturally occurring doses of 90,180 and 270 Billion CFU/day10. Stephen R. ;Friedman, Eli A. safe microbes possessing some uremic toxin There was a significant reduction in creatinine TheScientificWorldJOURNAL, 2005 (5), 652-660 catabolizing properties. Screening of 165 and C-reactive protein (CRP) an inflammatory 7. In vitro and in vivo Assessment of Intraintestinal probiotics strains, selecting a dozen and biomarker. Reduction was also seen in urea, Bacteriotherapy in Chronic Kidney Disease. Natarajan enhancing their growth in uremic milieu led to potassium and improvement in quality of life Ranganathan; Beena G. Patel; Pari Ranganathan; strains which could metabolize uremic toxins. In (QOL) were also observed. Joseph Marczely; Rahul Dheer; Bohdan Pechenyak; vitro and simulated gut studies led to the Stephen R. Dunn; Willy Verstraete; Karel Decroos; Raj formulation of the probiotic dietary supplement Mehta; Eli A. Friedman, ‘RENADYL™’ having a blend of three strains of Clinical Trial 3-Results ASAIO Journal 2006,70-79 8. Probiotic Dietary Supplementation in Patients with probiotic bacteria; S thermophilus(KB19), L Stage 3 and 4 Chronic Kidney Disease: A 6-month Pilot acidophilus(KB27) and B longum(KB31). Scale Trial in Canada. N. Ranganathan, E.A. Friedman, ‘RENADYL’ has a pharmaceutical like validation Variable Tx period N Mean P. Tam, V. Rao, P. Ranganathan, R. Dheer. Base 22 6.36 with various animal trials6,7,8 and also human Current Medical Research and Opinion, 2009, White Blood Cells (WBC) Placebo (PL) 21 6.07 trials in CKD/Dialysis patients. 25(8): 1919-1930. Treatment (Tx) 21 5.57 9. Pilot Study of Probiotic Dietary Supplementation for Base 21 8.89 Clinical Trial1-Results C-reactive protein (CRP) Placebo (PL) 18 11.28 Promoting Healthy Kidney Function in Patients with Chronic Kidney Disease. N. Ranganathan, P. Treatment (Tx) 19 5.1 Ranganathan, E.A. Friedman, A.Joseph, B.Delano, D.S. . Base 22 0.75 Total Indoxyl Glucuronide (TIG) Placebo (PL) Goldfarb, P. Tam, A.V. Rao, E. Anteyi, C.G. Musso. 22 0.75 No of Patients % of Patients Advances in Therapy, 2010, 27(9): 634-647. Parameter showing showing p value Treatment (Tx) 22 0.67 10. Dose Escalation, Safety and Impact of a Strain- positive positive Specific Probiotic (RENADYL™) on CKD Stages III and response response IV Patients. Natarajan Ranganathan, Pari Ranganathan, Blood Urea Nitrogen (BUN) 29 63 <0.05 Variable Tx period t value Pr>ǀt ǀ Usha Vyas, Bohdan Pechenyak, Stephanie DeLoach, Creatinine (Crn) 20 43 Not statistically White Blood Cells (WBC) PL-Tx 2.03 0.0569 Bonita Falkner, Alan Weinberg, Subodh J. Saggi and Eli Uric Acid 15 33 significant A Friedman. Quality of Life 8 86 <0.05 C-reactive protein (CRP) PL-Tx 1.97 0.0707 J Nephrol Ther 2013,3:141. doi: 10.4172/2161- Total Indoxyl Glucuronide (TIG) PL-Tx 2.01 0.0579 0959.10001417. Multi center double blind placebo controlled 11. Randomized Controlled Trial of Strain-Specific crossover studies in CKD III and IV patients, for a Probiotic Formulation (Renadyl) in Dialysis Patients. Double blind placebo controlled crossover 6 month period9. Ranganathan Natarajan, Bohdan Pechenyak, Usha studies in 22 dialysis patients over a 6 month Dosage of 90 Billion CFU/day. Vyas, Pari Ranganathan, Alan Weinberg, Peter Liang, period at the State University of New York Mary C. Mallappallil, Allen J. Norin, Eli A. Friedman, and USA- SUNY and NYU school of Medicine(n=10), showed reduction in CRP, serum total Indoxyl Subodh J. Saggi. Canada-University of Toronto, Scarborough glucuronide (IG) and improved QOL with a dose BioMed Research International Volume 2014, Hospital Ontario (n=13), Nigeria-National Hospital of 180 Billion CFU/day11. Article ID 568571 Abuja (n=15), Argentina-Hospital Italiano Bueno Aires(n=8) An identical poster was presented at the Harvard probiotic symposium “Gut Microbiota, Probiotics and Their Impact Throughout the Lifespan” on September 22-23, 2014 at the Harvard Medical School, Boston, MA.